Poster Session - Day 2

Preparing and Presenting your poster:

  • Please make the dimensions of your poster no larger than 4’ high X 6’ long. 
  • Pushpins and Velcro will be available.  
  • Presenters are requested to stay near their posters during the poster session to field questions and discuss their findings.

 

                             POSTER SESSION - DAY 2, October 9, 2024

 

Abstract/
Poster #

Name

Title

2

Daley, Brianna

SOS1 inhibition enhances the efficacy of and delays resistance to G12C inhibitors in lung adenocarcinoma 

4

Yavuz, Bengi Ruken

Anticancer Target Combinations: A Network-Informed Signaling-Based Approach to Discovery

8

Messing, Simon

Improved Production of Class I Phosphatidylinositol 4,5-bisphosphate 3-kinase

10

Shukla, Hem

synergistic interaction of HIf1α and KRAS leads to tumor aggression and radiation resistance in pancreatic cancer 

12

Wang, Junwei

ADT-007, a 1st-in-class pan-RAS inhibitor with a unique mechanism of RAS selectivity 

14

Ongey, Elvis

Biochemical and mechanistic insights into NRas depalmitoylation by ABHD17 

16

Nuevo Tapioles, Cristina

BIRC6 Ubiquitinates KRAS4A

18

Finniff, Bridget

Wild-type RAS signaling is an essential therapeutic target in RAS-mutated cancers

20

Martinez, Orlando

Investigating RAS guanine nucleotide exchange factor SOS1 negative feedback regulation by RSK1-mediated 14-3-3 association 

22

Xu, Liang

Allosteric Modulation of NF1 GAP Activity 

24

Timar, Jozsef

Farnesyltransferase inhibitors potentiate antitumoral effects of mutant KRAS inhibitors in preclinical models of cancers 

26

Vena, Francesca 

Characterization of a Panel of CRISPR/Cas9 Engineered KRAS G12C Inhibitor-resistant Tumor Models 

28

Ackermann, Sarah

Identifying Metabolic Requirements for RAS Inhibitor Resistance in Pancreatic Cancer 

30

Whitley, Matthew

Comparative analysis of KRAS4a and KRAS4b splice variants reveals distinctive structural and functional properties

32

Stephen, Andy

RRAS2 allosterically regulates SOS. 

34

Mundra, Surbhi

Characterization of Kinetic and Redox Properties of Oncogenic KRASG12C Inhibitors   

38

Ozawa, Hiroki

KRAS Mutant Lung and Pancreatic Cancers are Dependent on MUC1-C for Resistance to KRAS Inhibitors

42

Todd, Haley

CK2-dependent MYC phosphorylation regulates MYC protein stability and response to KRAS inhibition in pancreatic cancer

44

Mukherjee, Priyanjali

Post-transcriptional Control of SRSF9 Promotes the Epithelial-to-Mesenchymal Transition in Colorectal Cancer Cells

48

Molina-Arcas, Miriam

Investigating therapeutic strategies to overcome development of resistance to KRASG12C inhibitors and enhance anti-tumour immunity

50

Araki, Toshiyuki

Structure-function analysis in mice unexpectedly reveals that SHP2 catalytic activity is dispensable for early mouse development and RAS activation by EGFR and FGFR. 

52

Borthakur, Gautam

Targeting ERK1/2 in Acute Myeloid Leukemia: Impact on Mitochondrial Dynamics to Overcome Resistance 

54

Mira, Alessia

EML4-ALK mediates resistance to KRAS G12C inhibition   

56

Frone, Megan

RNA studies and somatic second hit data clarify classification of a RASA1 intronic variant in a patient with capillary malformation-arteriovenous malformation syndrome with Parkes Weber phenotype 

58

Drizyte-Miller, Kristina

Combination of MTA-Cooperative PRMT5 Inhibitor MRTX1719 and KRAS Inhibitors for the Treatment of MTAP-Deficient KRAS-Mutant Pancreatic Cancer 

60

Degan, Seamus

Characterization of the ULK-Regulated Proteome in KRAS-driven Pancreatic Cancer 

62

Hibshman, Priya

Defining the role of MYC in KRAS-mutant pancreatic cancer 

64

Kim, Hyungdong

Translation initiation factor eIF2B is essential for the stimulation of SOS:mutant KRAS function and LUAD tumorigenesis.

66

Huang, Chunghui

Robust antitumor activity in mouse pancreatic cancer models of an orally bioavailable prodrug of ADT-007, a 1st-in-class pan-RAS inhibitor. 

68

Tan, Stanley

Testing receptor desolvation scoring for molecular docking to RAS proteins

70

Andrade Bonilla, Pedro

Live cell FLIM-FRET investigation highlights differential interaction of RAS oncogenes with plasma membrane lipids. 

72

Downward, Julian

Development and Characterization of Covalent Inhibitors of the RAS-PIK3CA interaction 

74

Chakrabarti, Mayukh

Generative Molecular Design: Application of an in-silico molecular generation pipeline towards the discovery of potential RAS therapeutics 

76

Fields, Kristie

Increasing Cancer Clinical Trial Participation in Underserved Communities 

78

Guterres, Adam

SNP-specific CRISPR: Uncovering EphA2 and DUSP4 as therapeutic vulnerabilities in NRAS-mutant melanoma 

80

Yohe, Marielle

Echocardiographic and behavioral analysis of adult Mek1(Y130C) mice 

82

Yohe, Marielle

Functional characterization of novel germline HRAS variants

84

Solanki, Hitendra

 Combining RAS(ON) G12C-selective and RAS(ON) multi-selective inhibitors overcomes sotorasib resistance driven by KRASG12C amplification or NRASG13R mutation 

86

Taylor, Khalilah

Elucidation of Novel Avutometinib-Anchored Inhibitor Combinations for Pancreatic Cancer 

88

Columbus, John

Development of a high-throughput cell-based assay to interrogate RAS-lipid interactions 

90

Messerli, Shanta

Evaluating Macromolecular Antioxidants for Reducing Chemotherapy-Induced Adverse Events and Modulating Tumor Progression in a Metastatic Triple-Negative Breast Cancer Mouse Model

92

DeLiberty, Jonathan

PIKfyve Inhibition Enhances the Efficacy of RAS-ERK MAPK Inhibitors in Pancreatic Cancer 

94

Kabiri, Zahra

KRAS G12V Mutation Is Associated with Better Prognostic Advantage in Early-Stage Pancreatic Ductal Adenocarcinoma. 

96

Bishop, Cassie

Presentation Title: Loss of the UBE2F-CUL5 axis mediates resistance to KRAS inhibition in pancreatic cancer 

104

Mukti, Roushney Fatima

Role of RAS Nanoclustering in the Activation of RAL By RALGDS 

106

Neumann, Jacob (withdrawn)

Survivin Promotes the Warburg Effect in KRAS-dependent Cancer Cells by Interacting with a Key Metabolic Enzyme 

108

Lieschke, Elizabeth

Diacylglycerol kinase inhibition improves treatment response in KRAS mutant lung cancer 

110

Kato, Ryoji

In situ RAS:RAF binding correlates with response to KRASG12C inhibitors in KRASG12C-mutant non–small cell lung cancer 

114

Gulay, Kevin Christian 

Understanding MRTX1133 Resistance in Pancreatic Cancer: The Role of Tumor Microenvironment Modulation in Developing Alternative Therapeutic Strategies 

116

Gitego, Nadege

BBO-11818, an orally bioavailable, highly potent and non-covalent pan-KRAS  inhibitor demonstrates robust anti-tumor activity in KRASG12D and KRASG12V preclinical models 

118

Stern, Yaakov

Targeting CDK12/13 overcomes acquired resistance to KRASG12C inhibitors in NSCLC 

120

Xing, Bowen

RAB27B Controls NRAS Activity, Trafficking, and Stability in Acute Myeloid Leukemias  

122

Stamey, Addison

Overcoming KRASG12D inhibitor resistance in pancreatic ductal adenocarcinoma: insights from KEAP1-driven mechanisms and combination therapy approaches 

124

Esposito, Dom

Receptor tyrosine kinases may play a dual positive and negative regulatory role in RAS-MEK-ERK signaling 

126

Hook, Sara

Building High-Performing R&D Cultures and Empowering the Next Generation of Scientific Leaders

P2

Dash, Subhra

Investigating mechanisms responsible for MAP kinase pathway resistance in RAS-altered Neuroblastoma cells.

P4

Odeniyide, Patience

Combined inhibition of farnesyltransferase and MEK inhibits growth and promotes myogenic differentiation in HRAS-mutant rhabdomyosarcoma

P6

Bialousow, Lucas

PTEN oxidation drives elevated PI3K signaling in KRAS driven PDAC 

P8

Vaseva, Angelina

Evaluation of the RAF/MEK Clamp Avutometinib in RAS-driven Rhabdomyosarcoma

P10

Stronach, Beth

Unmet Needs in the RASopathies 

P12

Farouk Sait, Sameer

Hydroxychloroquine prevents resistance and potentiates antitumor effect of SHP2 inhibition in NF1-associated Malignant Peripheral Nerve Sheath Tumors